This segment focuses on the research, development, and clinical evaluation of allogeneic cell therapies for various oncology indications. Kiromic utilizes its proprietary DIAMOND® AI platform to identify and validate novel targets, design and engineer gamma delta T cell therapies, and conduct preclinical and clinical studies. The primary focus is on developing CAR-T cell therapies, including ALEXIS-ISO-1 targeting Isomesothelin and ALEXIS-PRO-1 targeting PD-L1. The company is also working on chimeric gamma delta PD1 T cell switch receptor therapy. This segment addresses unmet needs in cancer treatment by providing off-the-shelf cell therapies, potentially improving patient outcomes and expanding access to innovative treatments. Partnerships with institutions like Gemelli Teaching Hospital and Mercer University support clinical trial analysis and research advancements. Future opportunities include expanding the pipeline to additional cancer types and advancing clinical trials to later stages.

This segment leverages Kiromic's proprietary DIAMOND® AI platform for target discovery and gene editing. The platform analyzes vast datasets to identify novel targets for cancer immunotherapy. This involves utilizing machine learning and data analytics to predict the efficacy and safety of potential therapeutic targets. The company's research and development activities include identifying alternatively spliced targets, leading to the potential discovery of novel 1st and 2nd-line targets. This segment's focus is on improving the precision and efficiency of drug development, potentially leading to more effective and targeted cancer treatments. The company's competitive advantage lies in its AI-driven approach, which accelerates the identification of promising therapeutic candidates. Future opportunities include expanding the application of the DIAMOND® platform to other disease areas and partnering with pharmaceutical companies to discover and develop new therapies.